Listen to Dr. Harpreet Wasan commenting on the endpoint of PFS at any site.

Dr. Wasan’s key comments and takeaways:

  • Patients in the SIRFLOX study had a bad prognosis, as patients with limited disease outside the liver were allowed to enroll in the study; over 40% of SIRFLOX patients had their primary tumor in situ, and 90% had synchronous disease.
  • Patients with synchronous disease often have multiple sites of disease at the first presentation. As the number of visible metastases increases, the number of micro metastases most likely increases as well but cannot be seen at time of diagnosis. Dr. Wasan assumes that the majority of patients had micro metastases outside the liver that progressed upon systemic therapy.

Now leaving

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.



You are now leaving your current region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.